Pfizer Raises Full-Year Profit Guidance, Expects Higher Covid-19 Vaccine Sales
04 May 2021 - 9:36PM
Dow Jones News
By Matt Grossman
Pfizer Inc. on Tuesday raised its full-year revenue and earnings
guidance, citing a higher estimate of sales of its Covid-19
vaccine.
Pfizer now expects full-year revenue of $70.5 billion to $72.5
billion, compared with previous guidance for revenue of $59.4
billion to $61.4 billion.
The company forecast a full-year adjusted profit of $3.55 a
share to $3.65 a share. It had previously said it expected an
adjusted profit of $3.10 a share to $3.20 a share.
Pfizer expects its Covid-19 vaccine developed with BioNTech SE
to generate revenue of about $26 billion in the year. It had
previously guided for revenue of about $15 billion from the
shot.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
May 04, 2021 07:21 ET (11:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024